Yup i went to the clinical research doc today. Mere 15% for cirrotic 1a non responders. Sigh. The did say new drugs show hope as the cocktail approach enlarges but it is unlikely that cirrotic non respomders will be excepted in the first studies, just non responders. Perhaps that 15 will go to 40 with additional drugs so ill just hang in there till these new additions become available in trials. Lots of love to all you special med help people.
What is on the horizon for null-responders in that you only have one
chance with these kinds of medications.
Also, in cirrhotic patients who were previous null-responders, the rate of SVR drops to less than 15% with triple therapy.
Just to add to what flcyclist has posted.... The other protease(Victrelis) in trial for previous treatment patients showed:
SVR :75% for relapsers and 52% for partial responders.
Null responders( <2 log drop by wk.12 on a prev. tx) were not included in trial.
Will
Overall, the SVR rates in patients with prior relapse, partial response and non-response were 86, 58 and 32% respectively with teleprevir. Patients who do not achieve a RVR, those with cirrhosis and certain prior non-responders should be treated for 48 weeks.
http://hepatitiscnewdrugs.blogspot.com/2012/01/triple-therapy-for-hcv-geno1-telaprevir.html
BMS Oral Hep C Drug Combo Cures 90% of Null Responders With Genotype 1b in Japanese Study
http://www.hepmag.com/articles/daclatasvir_asunaprevir_daa_2501_21511.shtml
http://www.hepctrust.org.uk/Treatment/Potential+New+Drugs/Drugs+that+target+the+virus/BMS+Daclatasvir+plus+Asunaprevir